- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00148330
Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study
An Open Label Extension of the Phase II/III Clinical Trial of Intravitreal Triamcinolone on the Effects and Safety of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment
This open label extension will treat all the eyes of study participants with active study medication (intravitreal triamcinolone) as well as standard laser treatment where appropriate.
The specific aims will be to test the following hypotheses:
- That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment remains efficacious over five years
- That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment retains a manageable and acceptable safety profile over five years
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2000
- Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participation in the study will be offered to all patients at the conclusion of the TDMO study. Currently we are still following 64 of the 69 (93%) eyes that were initially entered into the study that had reduced vision from diabetic macular oedema at baseline.
Exclusion Criteria:
- Uncontrolled glaucoma
- Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration)
- known allergies to triamcinolone acetate, patient is already receiving systemic steroid treatment, intercurrent severe disease such as septicemia, any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase of ≥5 letters at the 5-year study visit on a LogMAR chart compared with (a) the initial baseline level and (b) the level at the 2-year study visit.
Time Frame: 3 year extension, total 5 years study from baseline
|
Changes from Baseline to 5 years: Improvement of ≥5 letters after 5 years was found in 14/33 (42%) eyes initially treated with triamcinolone compared with 11/34 (32%) eyes initially treated with placebo (zGEE=0.81, P=0.4). Changes from 2 to 5 years (open-label extension):Improvement of ≥5 letters of best-corrected visual acuity was found in 8/29 (28%) eyes initial-triamcinolone compared with 7/28 (25%) initial-placebo eyes (zGEE=0.20, P=0.8). |
3 year extension, total 5 years study from baseline
|
Incidence of moderate or severe adverse events over the 3 years of the open-label extension
Time Frame: 3 year extension study, total 5 year study from baseline
|
The incidence of cataract surgery declined in the third year: 5/11 (45%) eyes from the initial-triamcinolone group that were phakic at the beginning of the 3rd year required cataract surgery.
|
3 year extension study, total 5 year study from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in macular thickness by OCT
Time Frame: 3 year extension, total 5 year study from the baseline
|
Changes from Baseline to 5 years: Foveal thickness had decreased by 30µm (95% confidence interval, -47 to 107µm) less in the initial-triamcinolone group than in the initial-placebo group at 5 years (zGEE=0.76, P=0.45). Changes from 2 to 5 years (open-label extension):Foveal thickness had actually increased slightly on average in the initial-triamcinolone group, but decreased in initial-placebo eyes. Overall it had decreased by 70µm (95% confidence interval, -1 to 140µm) more in the placebo group than in the treatment group between 2 and 5 years (zGEE=1.93, P=0.05). |
3 year extension, total 5 year study from the baseline
|
Any change in visual acuity
Time Frame: 3 year extension, total 5 year study from the baseline
|
Loss of ten or more letters was found in 6/33 (18%) initial-triamcinolone eyes compared with 8/34 (24%) initial-placebo eyes.
|
3 year extension, total 5 year study from the baseline
|
Number of laser treatments required.
Time Frame: 3 year extension study, total 5 year study from baseline
|
During the third to fifth years of the study, a similar proportion of eyes from the 2 groups had macular edema that warranted laser treatment: initial-triamcinolone, 5/29 (17%); initial-placebo, 6/28 (21%).
|
3 year extension study, total 5 year study from baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark C Gillies, MBBS, PhD, Save Sight Institute, Deaprtment of Clinical Ophthalmology, University of Sydney
Publications and helpful links
General Publications
- Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005 May;139(5):802-6. doi: 10.1016/j.ajo.2004.12.054.
- Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004 Nov;111(11):2044-9. doi: 10.1016/j.ophtha.2004.05.025.
- Kuo CH, Gillies MC. Role of steroids in the treatment of diabetic macular edema. Int Ophthalmol Clin. 2009 Spring;49(2):121-34. doi: 10.1097/IIO.0b013e31819fcce8. No abstract available.
- Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter F. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology. 2009 Nov;116(11):2182-7. doi: 10.1016/j.ophtha.2009.04.049. Epub 2009 Oct 1.
- Gillies M. Diabetic macular edema. Ophthalmology. 2009 Mar;116(3):595; author reply 596-7. doi: 10.1016/j.ophtha.2008.12.016. No abstract available.
- Gillies MC, Simpson JM, Zhu M, Hunt G, Ali H, Gaston C. Intravitreal triamcinolone. Ophthalmology. 2009 Mar;116(3):591. doi: 10.1016/j.ophtha.2008.09.044. No abstract available.
- Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006 Sep;113(9):1533-8. doi: 10.1016/j.ophtha.2006.02.065. Epub 2006 Jul 7.
- Larsson J, Kifley A, Zhu M, Wang JJ, Mitchell P, Sutter FK, Gillies MC. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol. 2009 May;87(3):275-80. doi: 10.1111/j.1755-3768.2008.01245.x. Epub 2008 Sep 10.
- Wickremasinghe SS, Rogers SL, Gillies MC, Zhu M, Wong TY. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4707-11. doi: 10.1167/iovs.08-1678. Epub 2008 Jul 3.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NHMRC project 402573
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Oedema
-
University of SydneyCompletedDiabetic Macular OedemaAustralia
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
AllerganCompletedDiabetic Macular OedemaAustralia
-
University of OxfordPfizerCompletedDiabetic Macular OedemaUnited Kingdom
-
Odense University HospitalMoorfields Eye Hospital NHS Foundation TrustCompletedDiabetic Macular OedemaDenmark
-
University of SydneyUniversity of Melbourne; The University of Western Australia; Marsden Eye SpecialistsCompletedDiabetic Macular OedemaAustralia
-
Ripple Therapeutics Pty LtdNovotech (Australia) Pty LimitedActive, not recruitingDiabetic Macular Oedema | Retinal Vein Occlusion With Macular OedemaAustralia, New Zealand, Hong Kong, Canada
-
Alimera SciencesUnknownChronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available TherapiesUnited States
-
Glostrup University Hospital, CopenhagenCompletedDiabetic Macular OedemaDenmark
-
Glostrup University Hospital, CopenhagenTerminatedDiabetic Macular OedemaDenmark
Clinical Trials on Triamcinolone acetate
-
University of SydneyCompletedDiabetic Macular OedemaAustralia
-
Goldman, Butterwick, Fitzpatrick and GroffAllergan; Maryland Laser Skin and Vein InstituteCompleted
-
University of SydneyUniversity of Melbourne; The University of Western Australia; Marsden Eye SpecialistsCompletedDiabetic Macular OedemaAustralia
-
Ramathibodi HospitalCompletedLumbar Disc Herniation
-
Tel-Aviv Sourasky Medical CenterUnknownScars | Keloid | Hypertrophic Scar | Scarring
-
The First Affiliated Hospital of Zhejiang Chinese...Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine; Pujiang... and other collaboratorsRecruiting
-
Istituto Ortopedico RizzoliAzienda Ospedaliera San Giovanni BattistaCompletedTendinopathy | Adrenal InsufficiencyItaly
-
Keesler Air Force Base Medical CenterCompletedShoulder Pain | Subacromial BursitisUnited States
-
ROC FoundationCompletedOsteoarthritis, KneeUnited States
-
China Medical University HospitalUnknown